Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.
Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.
Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.
Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.
Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.
He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.
Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.
1401, 18e rue
G4.613
Québec, QC
Canada G1J 1Z4
- Brisson, HervéEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension 16849+1 418-691-5562herve.brisson@crchudequebec.ulaval.ca
10, McMahon
1875
Québec, Québec
Canada G1R 2J6 - Gagné, ChristineEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension 67709christine.gagne@crchudequebec.ulaval.ca
1401, 18e rue
G4.612
Québec, QC
Canada G1J 1Z4 - Verret, NadiaEmployee+1 418-525-4444, extension 16849
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression
Journal ArticleJ Clin Invest, 134 (11), 2024.
Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes
Journal ArticleFront Immunol, 15 , 2024.
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC
Journal ArticleCan Urol Assoc J, 18 (2), 2024.
Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada
Journal ArticleHum Pathol, 146 , 2024.
A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation
Journal ArticleCommun Med (Lond), 4 (1), 2024.
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer
Journal ArticleBr J Cancer, 128 (2), 2023.
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer
Journal ArticleMol Oncol, 17 (10), 2023.
Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)
Journal ArticleNutrients, 15 (6), 2023.
Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer
Journal ArticleJ Urol, 209 (2), 2023.
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways
Journal ArticleCancer Lett, 553 , 2023.
Active projects
- A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma, from 2023-09-22 to 2028-12-25
- Metabolomics and lipidomics of prostate cancer progression: Leveraging the PROCURE Biobank, from 2024-07-10 to 2025-03-31
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , from 2024-06-17 to 2025-06-16
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31
Recently finished projects
- Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31
- Soutien à la recherche, from 2017-07-01 to 2024-06-30